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Aim: To explore effects of Artemisinin on a series of breast cancer cells with different sensitivity to typical cytotoxic drugs (doxo-
rubicin — Dox; cisplatin — DDP) and to investigate possible artemisinin-induced modification of the mechanisms of drug resistance. 
Materials and Methods: The study was performed on wild-type breast cancer MCF-7 cell line (MCF-7/S) and its two sublines 
MCF-7/Dox and MCF-7/DDP resistant to Dox and DDP, respectively. The cells were treated with artemisinin and iron-con-
taining magnetic fluid. The latter was added to modulate iron levels in the cells and explore its role in artemisinin-induced effects. 
The MTT assay was used to monitor cell viability, whereas changes of expression of selected proteins participating in regulation 
of cellular iron homeostasis were estimated using immunocytochemical methods. Finally, relative expression levels of miRNA-200b, 
-320a, and -34a were examined by using qRT-PCR. Results: Artemisinin affects mechanisms of the resistance of breast cancer 
cells towards both Dox and DDP at sub-toxic doses. The former drug induces changes of expression of iron-regulating proteins 
via different mechanisms, including epigenetic regulation. Particularly, the disturbances in ferritin heavy chain 1, lactoferrin, 
hepcidin (decrease) and ferroportin (increase) expression (р ≤ 0.05) were established. The most enhanced increase of miRNA 
expression under artemisinin influence were found for miRNA-200b in MCF-7/DDP cells (7.1 ± 0.98 fold change), miRNA-320a 
in MCF-7/Dox cells (2.9 ± 0.45 fold change) and miRNA-34a (1.7 ± 0.15 fold change) in MCF-7/S cells. It was observed that 
the sensitivity to artemisinin can be influenced by changing iron levels in cells. Conclusions: Artemisinin can modify iron metabolism 
of breast cancer cells by its cytotoxic effect, but also by inducing changes in expression of iron-regulating proteins and microRNAs 
(miRNAs), involved in their regulation. This modification affects the mechanisms that are implicated in drug-resistance, that makes 
artemisinin a perspective modulator of cell sensitivity towards chemotherapeutic agents in cancer treatment.
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Resistance to anticancer drugs is one of t�e major 
complications during t�e treatment of cancer patients 
because it causes low efficiency even of �ig�ly toxic 
treatment regimens.
T�ere are two generally accepted forms of reduced 
sensitivity of cancer cells to cytotoxic drugs and �or­
mones including initial resistance� w�en tumor cells 
are initially not sensitive to t�erapy because of c�anges 
in metabolism caused by mutations in key gene effec­
tors and secondary resistance t�at develops because 
of t�e survival of tumor cell clones during t�e initial 
treatment [�].
�ec�anisms� w�ic� are in�erent to malignant cell 
transformation� constitute also t�e basis of resis­
tance towards anticancer drugs namely: �� violation 
of signaling pat�ways and metabolism; �� violation 
of t�e cell cycle� reparative processes; �� epigenetic 
c�anges; 4� mutations in t�e genes t�at encode t�e 
targets of anticancer drugs [�].
T�erefore� resistance to c�emot�erapy and mole­
cular targeted t�erapy is a serious problem t�at affects 
not only survival but also a quality of life of patients. 
For example� it is known t�at adjuvant and postope­
rative c�emot�erapy� w�ic� are used in metastatic 
cases of breast cancer �BC�� often are ineffective. 
T�is necessitates t�e searc� for drugs t�at will be ef­
fective against t�e tumors of t�is localization resistant 
to ant�racyclines and taxanes. In suc� cases in clinical 
practice combination t�erapy is used. However� t�e 
range of suitable drugs is narrow due to t�e develop­
ment of multiple resistance. A promising approac� 
in t�is situation is not only t�e searc� for new� less 
toxic and more potent c�emot�erapeutic agents but 
also t�e exploration of t�e possibility of overcoming t�e 
resistance of tumor cells to already known cytotoxic 
drugs. In particular� t�e use of low­toxic drugs t�at 
�ave long been used as t�erapeutic agents for t�e 
treatment of non­cancer pat�ologies and affect t�e 
altered metabolism of tumor cells is of great interest. 
One of t�ese drugs is artemisinin [�].
T�e plant Artemisia annua was used in C�inese 
medicine before our era. In ����� C�inese scientists 
isolated t�e active ingredient� a sesquiterpene lac­
tone� called artemisinin� w�ic� is responsible for t�e 
anti­parasitic effect of t�is plant. In recent years� t�e 
drug �as become t�e gold standard for malaria treat­
ment [�]. In ���� c�emist Tu Youyou was awarded t�e 
Nobel Prize for discovery of artemisinin [4].
During primary testing of a new substance in ex­
periments in vitro� its antitumor activity for t�e different 
cancer types� from �epatocellular carcinoma to t�e 
breast tumors was detected [�].
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In recent years� interest in artemisinin and its deri­
vatives as antitumor drugs �as increased significantly. 
T�ere are a lot of reports of t�eir successful use in clini­
cal practice as separate medication and in combination 
wit� cytotoxic drugs [6].
Along wit� above mentioned� t�ere is an evidence 
about t�e particular artemisinin impact on BC cells 
by one of its mec�anisms of action mediated by estro­
gen receptor signaling pat�way [�]. However� despite 
active researc�� all mec�anisms of artemisinin antitu­
mor action are not establis�ed yet. In addition� t�ere 
are a lot of �ypot�eses about its ability to adjust t�e 
cancer cell sensitivity to cytotoxic drugs t�at require 
a more detailed study.
MATERIALS AND METHODS
Cell lines and drug treatment. T�e studies 
were conducted in an in vitro system on � cell lines 
of �uman mammary: �CF­� — invasive breast ductal 
carcinoma sensitive and resistant to cytotoxic drugs; 
�DA­�B­��� and �DA­�B­468 — metastatic breast 
adenocarcinoma.
T�ree sub­lines of breast carcinoma �CF­� cells� 
namely �CF­�/S� sensitive to cytostatics; �CF­�/
Dox — resistant to doxorubicin �Dox�; and �CF­�/
DDP — resistant to cisplatin �DDP� were grown 
in Dulbecco �odified Eagles �edium �D�E�� 
Sigma�� supplemented wit� recombinant �uman 
insulin ��.�� mg/ml� and ��% fetal bovine serum. 
�DA­�B­��� and �DA­�B­468 cells were cultured 
in Leibovitz’s L­�� medium �Sigma� supplemented 
by ��% fetal bovine serum. All cultures were grown 
in �umidified atmosp�ere wit� �% CO� at �� °C. Cells 
were provided by t�e Bank of Cell Lines of Human and 
Animal Tissues at R.E. Kavetsky Institute of Experi­
mental Pat�ology� Oncology and Radiobiology of t�e 
NAS of Ukraine and described earlier [8].
Measurement of cell viability, using the MTT 
assay. For t�is purpose� cells were cultivated in �6­
well plates in D�E�� supplemented wit� insulin �see 
above�. T�e artemisinin �Sigma­Aldric�� USA�� Dox 
�Ebewe� Austria�� and DDP �Ebewe� Austria� were 
added to media at different concentrations and t�e 
cells were cultivated for eit�er �4 or 48 �. For t�is pur­
pose artemisinin was diluted in �.��% D�SO in media. 
After t�is time� �� µl of t�e �TT dye solution �Sigma� 
USA� �� mg/ml in p�osp�ate buffer saline� was added 
to t�e cells; t�e cells were incubated at t�e same con­
ditions for � �. After centrifugation ����� rpm� � min� 
t�e supernatant was removed. ��� µl of dimet�yl 
sulfoxide �Serva� Germany� was added to eac� well� 
to dissolve formazan. T�e absorption was measured� 
using a multi­well spectrop�otometer �STAT FAX ����� 
USA� at a wavelengt� of �4� nm [�].
Total RNA isolation. Total RNA extraction was 
performed� using Ribozol RNA Isolation Kit �Amplisens� 
Russia�. Concentration of RNA was measured� using 
NanoDrop ����c Spectrop�otometer �T�ermo Scien­
tific� USA�. T�e purity of isolated RNA was controlled� 
analyzing t�e ratio of OD at �6�/�8� nm. RNA was 
dissolved in TE buffer and stored at −�� °С.
Single­stranded cDNA was synt�esized from 
��� ng of total RNA� using Taq�an® �icroRNA Kit for 
reverse transcription.
Real-time quantitative reverse transcription 
polymerase chain reaction (qRT-PCR). Preparation 
of reverse transcription reaction mix was performed 
according to manufacturer’s protocol. Reverse 
transcription was performed at a “Tertsik” �DNA 
Te�nologіya� Russian Federation� t�ermal cycler. qRT­
PCR was performed on Applied Biosystems ����HT 
Fast Real­Time PCR System using Taq�an® �icroRNA 
primers and manufacturer’s protocol.
Small nucleolar RNA RNU48 was used as an endo­
genous control for normalization of miRNA expression. 
Relative expression of t�e studied miRNAs was iden­
tified by comparative Ct met�od. Experiments were 
performed in triplicates for eac� line� and PCR was 
performed t�ree times for eac� sample. Expression 
differences between t�e studied miRNA levels relative 
to control was calculated by t�e formula:
Fold change = 2−ΔΔCt�
w�ere ΔCt �target — control� is equal to t�e dif­
ference between t�res�old cycles for miRNA �target� 
and t�e t�res�old cycle for RNU48 �control� �ΔCt 
�target — control� = Ct target − Ct control�. ΔΔCt = ΔCt 
�experiment� − ΔCt �control�.
Immunocytochemical study. T�e expression 
level of transferrin receptor �CD���� ferritin �eavy 
c�ains � �FTH��� ferroportin A �SLC�� �epcidin �HEP� 
and lactoferrin �LF� were estimated using t�e im­
munocytoc�emical met�od. Cells for immunocyto­
c�emical studies were grown on glass cover slips� 
fixed in cooled mixture of met�anol:acetone ��:�� at 
−�� °C for ��� min� was�ed in p�osp�ate buffered 
saline �PBS� and incubated wit� �% bovine serum 
albumin for �� min. Primary monoclonal antibodies: 
CD�� �Bioworld Tec�nology� �inneapolis� �N� USA�� 
FTH� �GeneTex� Irvine� CA� USA�� SLC �Abcam� USA�� 
LF �T�ermoScientific� USA� та НЕР �Abcam� USA� 
were diluted in t�e blocking buffer and kept at a room 
temperature for one �our� followed by incubation wit� 
UltraVision LP Detection System �Lab Vision� T�ermo 
Scientific� for �� and �� min; after t�e was�ing� t�e 
immune reaction was visualized by using DAB Quanto 
�T�ermo Scientific�. W�en immunocytoc�emical re­
actions were completed� t�e cells were stained wit� 
�ematoxylin by �ayer for ����� s and placed in Fara­
mount Aqueous �ounting �edium �DakoCytomation� 
Denmark�. Evaluation of t�e results was carried out 
in � visual fields by lig�t microscopy �× ����� oil im­
mersion� using t�e classical H­Score met�od:
S = 1 • N1+ + 2 • N2+ + 3 • N3+,
w�ere S is «H­Score» index; N�+� N�+ and N�+ 
are numbers of cells wit� low� medium or �ig� levels 
of marker expression.
It s�ould be noted t�at in previous studies we �ave 
identified biomolecular markers t�at c�aracterize t�e 
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metastatic potential and invasive activity of BC cells 
of abovementioned lines [��].
Low-temperature Fe(III) electron paramag-
netic resonance (EPR). After �4 � of culturing� t�e 
cells were scrapped� was�ed in PBS� centrifuged 
at ���� g for �� min at 4 ˚C and t�e pellet was re­sus­
pended in PBS. The suspension containing 2•106 cells 
was transferred into EPR tubes and immediately frozen 
in liquid nitrogen. T�e level of free iron was deter­
mined by a low­temperature EPR met�od [��]. Briefly� 
samples were maintained at −��6 ˚ C during recording 
of t�e spectra using a finger Dewar filled wit� liquid 
nitrogen. T�e following parameters were used for t�e 
low­temperature EPR: sweep widt� ���� G; frequency 
�.�� GHz; microwave power 4� mW; modulation am­
plitude ��.� G and modulation frequency ��� kHz. T�e 
g­value was calculated using t�e standard formula:
g = hv/βH,
w�ere � — Planck’s constant; v — frequency; 
β — Bo�r magneton; H — external magnetic field 
at resonance.
Statistical analysis. Experimental data were 
analyzed using t�e Student’s t­test. p­values less t�an 
�.�� were considered statistically significant. Statisti­
cal analysis of t�e obtained data was performed� using 
t�e Statistica 6.� software.
RESULTS AND DISCUSSION
We conducted determination of cytotoxic activity 
of t�e drug artemisinin in BC cell lines wit� t�e diffe­
rent sensitivity to DDP and Dox. We found t�at �CF­�/
Dox cell line is t�e most sensitive to t�e artemisinin 
treatment� w�ereas �CF­�/DDP cell line t�e least 
sensitive �Table ��. Furt�ermore� we establis�ed t�at 
t�e cultivation of artemisinin at t�e IC�� dose caused 
c�anges in t�e p�enotype of cells of eac� studied 
BC line. For example� �CF­�/DDP cells were c�arac­
terized by s�ape loss and appearance of t�e large 
number of vacuoles visible under 4�× magnification 
using t�e microscope. T�is indicates cytotoxic effect 
of artemisinin on t�ese cells.
Table 1. Artemisinin cytotoxicity in B cell lines with different sensitivity 
to cytostatic drugs
BC cell 
lines
Free iron con-
tent, spins/ml
24 h 48 h
IC30,  
μg/ml
IC50,  
μg/ml
IC30,  
μg/ml
IC50,  
μg/ml
MCF-7/S 0.56 ± 0.1•1016 2.5 ± 0.3 5.5 ± 0.6 1.1 ± 0.2 2.5 ± 0.5
MCF-7/Dox 0.346 ± 0.1•1016 1.3 ± 0.7 3.7 ± 0.4 0.6 ± 0.01 1.46 ± 0.3
MCF-7/DDP 1.15 ± 0.1•1016 1.9 ± 0.2 6.4 ± 0.7 1.3 ± 0.4 2.75 ± 0.5
According to t�e literature� one of t�e c�aracteris­
tics of tumor cells is elevated levels of iron� as it is cru­
cial in t�e synt�esis of DNA� proteins t�at transport 
oxygen during cell division [��� ��]. For example� by us­
ing t�e EPR­based assay� described in t�e experimen­
tal section of t�is paper� we determined t�at amount 
of EPR­active Fe�III� ions in different �CF­� cell lines 
is between 0.346 and 1.15•106 spins/cell. T�e level 
of iron ions was found to be dependent upon t�e re­
sistance degree of t�e cells towards c�emot�erapeutic 
agents. In particular� Dox­resistant cell line �CF­�/
Dox contains t�e lowest Fe�III� amount� DDP­resistant 
cell line �CF­�/DDP contains �.� fold and wild type 
cell line �CF­� — �.6 fold �ig�er amounts of Fe�III�. 
T�erefore� t�ese t�ree cell lines are a convenient model 
to validate w�et�er t�e Fe�III� level correlates wit� cyto­
toxicity of artemisinin �Table ��. Previously� it �as been 
reported by �es�nick et al. [��] t�at artemisinin and its 
derivatives �ave antitumor effects due to active lactone 
compound sesquiterpene peroxide� w�ic� interacts 
wit� iron ions and causes oxidative stress t�roug� t�e 
formation of free radicals. However� we found t�at 
t�e cytotoxicity was �ig�est for t�e cells ��CF­�/
Dox� wit� t�e lowest Fe�III� amounts� w�ereas t�at 
was lower for bot� ot�er cell lines wit� �ig�er Fe�III� 
amounts �Table ��. T�is result does not contradict t�e 
literature data due to t�e following considerations. 
T�e total amount of iron ions �Fe�III� + Fe�II�� in cells 
is tig�tly controlled. T�erefore� t�e �ig� level of Fe�III� 
ions indicates t�e low amount of Fe�II� ones. Since 
t�e latter ions are required for reductive activation 
of peroxo­bridge of artemisinin� it is logical t�at t�is 
prodrug is mostly efficiently activated in �CF­�/Dox 
cells wit� t�e lowest level of Fe�III� and� correspon­
dingly� t�e �ig�est level of Fe�II� ions.
Apart from its direct effect of intracellular oxida­
tive stress� it was found t�at t�e mode of cytotoxic 
action of artemisinin involves many protein targets. 
In particular� artemisinin activates p�8 �APK­kinase 
cascade regardless of t�e oxidative stress due to in�ibi­
tion of VEGF expression and cell migration. At t�e same 
time� it launc�es a number of anticancer pat�ways� 
including signaling via Pi�k­akt� Toll­like receptors and 
mediated by TGF­β. �oreover� t�is drug in�ibits migra­
tion and invasive activity of tumor cells by redu cing 
t�e level of disintegrins� metalloprotease �� �ADA� 
family� and EGFR and targets TCR� CD�8� CD4� CD8A 
and CTLA4 proteins [��]. Artemisinin and its deriva­
tives promote activation of apoptosis and affect t�e 
level of c­�YC in cancer cells. Particularly active iron­
activated di�ydroartemisinin increases p�osp�orylation 
of t�is protein and accelerates its degradation in pro­
teasomes [�4]. T�is effect may be t�e cause of t�e low 
sensitivity of �CF­�/DDP� despite t�e �ig� concentration 
of iron ions. In our previous study we establis�ed t�at 
t�is cell line is c�aracterized by reduced expression 
of proapoptotic proteins� in particular� BCL­� and Bax� 
involved in t�e development of resistance to DDP and 
�ig� tolerance to DNA damage. T�is is explained by t�e 
fact t�at one of t�e mec�anisms of DDP action is t�e 
formation of multiple single and double­stranded DNA 
breaks [��].
According to t�e literature� artemisinin �as t�e se­
lective cytotoxic effect on tumor cells due to c�anges 
in iron­regulating proteins expression. It is known t�at 
tumor cells� due to t�e �ig� concentrations of transfer­
rin receptors �CD��� on t�e plasma membrane actively 
absorb iron. Artemisinin covalently binds to CD�� re­
ceptors and t�us selectively enters t�e tumor cells 
regardless of t�e tumor type [4].
T�e mec�anism of artemisinin binding to CD�� re­
ceptors on t�e cell surface is similar to t�e mec�anism 
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of its binding to t�e �eme in cells of t�e Plasmodium 
malariae. Transferrin receptor binds transferrin­iron­
ions complexes and by endocytosis enters t�e cell� 
acting as artemisinin transporter. After t�e degradation 
of endocytic vacuole� artemisinin is released and re­
acts wit� iron ions in t�e cytoplasm of tumor cells. One 
of t�e most significant effects of t�is process is critical 
DNA damage� w�ic� provokes apoptosis. In addition� 
artemisinin and its derivatives make cytoplasmic free 
iron unavailable for inclusion in t�e biological pro­
cesses due to t�e palmityl accession from t�e lipid 
membrane of endocytic vacuoles [�].
Based on t�e facts mentioned above� one of t�e 
mec�anisms of t�e artemisinin impact on tumor cells 
is modified metabolism of iron proteins. T�erefore� 
we �ave investigated c�anges in expression of proteins 
involved in iron metabolism� response to redox stress 
and t�e formation of resistance to cytotoxic drugs us­
ing t�e immunocytoc�emical met�od. We found out 
t�at artemisinin treatment of �CF­� cells� sensitive 
and resistant to Dox and DDP� causes a decrease in ex­
pression of proteins suc� as LF� FTH�� and HEP. Also� 
we establis�ed t�e increase of SLC expression. We did 
not observe any significant c�anges in t�e key effector 
of artemisinin response — CD��. Establis�ed increase 
in t�e levels of expression of iron metabolism proteins 
in �CF�/DDP cells compared to ot�er lines are consid­
ered to be one of t�e possible mec�anisms of tolerance 
to �ig� artemisinin concentrations of t�is line �Table ��.
Table 2. Changes in the molecular profile of BC cells caused by cultiva-
tion with artemisinin
BС cell lines CD71 FТН1 LF HEP SLC
MCF-7/S 72.0 ± 3.1 195.0 ± 3.7 251.0 ± 2.2 136.0 ± 2.3 83.0 ± 3.4
MCF-7/S+A 70.0 ± 2.7 150.0 ± 2.7* 213.0 ± 2.3* 94.0 ± 3.4* 130.0 ± 3.1*
MCF-7/Dox 84.0 ± 2.5 79.0 ± 2.1 67.0 ± 1.9 207.0 ± 2.7 200.0 ± 4.2
MCF-7/Dox+A 80.0 ± 5.8 49.0 ± 1.5* 62.0 ± 2.5* 189.0 ± 4.3* 214.0 ± 2.7*
MCF-7/DDP 215.0 ± 3.8 296.0 ± 3.3 105.0 ± 3.7 220.0 ± 2.3 203.0 ± 1.7
MCF-7/DDP +A 220.0 ± 3.2 236.0 ± 2.5* 84.0 ± 2.4* 156.0 ± 1.3* 212.0 ± 3.1*
Note: A — artemisinin; *р ≤ 0.05 compared with cell lines without artemisinin.
Since substantial c�anges in t�e expression 
of iron metabolism proteins were observed upon 
t�e cell treatment wit� artemisinin� we conducted 
t�e cultivation of �CF­� cell cultures wit� a mixture 
of artemisinin and iron­containing magnetic fluid. 
T�e latter reagent is a source of iron ions and was 
used to increase amount of iron ions in cells. In t�is 
experiment we tested t�e �ypot�eses of iron­depen­
dent artemisinin activation in cancer cells [�����]. 
In particular� we discovered t�at t�e magnetic fluid 
in a concentration of �� mg/ml greatly increases t�e 
sensitivity of BC cells to artemisinin �Tables � and ��. 
T�us� in combination wit� t�e low toxicity agent �iron­
containing magnetic fluid� artemisinin can be consi­
dered as a potent anticancer agent.
Table 3. Artemisinin cytotoxicity in BС cell lines with different sensitivi-
ty to cytostatic drugs after treatment with iron-containing magnetic fluid 
in the dose of 30 μg/ml
BС cell lines 24 h 48 hIC30, μg/ml IC50, (μg/ml) IC30, μg/ml IC50, μg/ml
MCF-7/S 1.31 ± 0.11* 1.12 ± 0.29* 0.75 ± 0.22* 1.3 ± 0.1*
MCF-7/Dox 0.52 ± 0.23* 0.60 ± 0.16* 0.42 ± 0.01* 0.77 ± 0.05*
MCF-7/DDP 0.60 ± 0.15* 1.36 ± 0.35* 0.98 ± 0.31* 1.35 ± 0.24*
Note: *р ≤ 0.05 compared with cell lines without magnetic fluid treatment.
It is known t�at BC cells� w�ic� express estrogen re­
ceptor on t�e surface� are very sensitive to artemi sinin 
and its derivatives. Due to t�e influence of t�e drug 
in t�e estrogen­dependent cells� including �CF­� and 
T4�D� t�ere is in�ibition of expression of estrogen 
receptor α on an epigenetic level by blocking t�e avai­
lability of ESR� promoter to transcription factors [�].
We and ot�ers found t�at in addition to t�e in­
�ibition of steroid signaling cascades� artemisinin 
affects ot�er epigenetic mec�anisms regulating 
t�e expression of proteins. In particular� Hargraves 
et al. [�8] demonstrated t�at levels of miR­�4a affect 
t�e Artemisinin ability to stop t�e cell cycle of BC cells 
regardless of TP53 mutations. As it is known� miR­�4a 
is one of t�e effectors of p��­mediated apoptosis. Ar­
temisinin significantly increases t�e levels of miRNAs 
in �CF­� and T4�D cells but does not affect expression 
levels of p�� protein [�8].
As noted above� one of t�e mec�anisms of cell 
cycle arrest by artemisinin is CDK4­kinase pat�way. 
CDK4 is a direct target of miR­�4a. In addition� ex­
pression of t�is onco­suppressive microRNA affects 
t�e sensitivity to a wide range of cytotoxic drugs� in­
cluding DDP. Given t�e above� we �ave elucidated t�e 
effect of artemisinin on t�e expression of miR­�4a and 
a number of ot�er miRNAs� w�ic� are involved in t�e 
development of BC cell resistance to anticancer drugs. 
In particular� in previous studies� we found t�at t�e de­
velopment of resistance to DDP and Dox in �CF­� cells 
is associated wit� lower levels of miR­���b� ­���a and 
c�anges of t�e expression of miR­�4a [��].
�iR­���b and ­���a bot� participate in t�e 
regulation of intracellular iron metabolism. T�e target 
of miR­���b is a ferritin �eavy c�ain mRNA and t�e 
target of miR­���a is mRNA of CD��. For example� 
increased expression of miR­���a reduces t�e level 
of CD�� on t�e surface of tumor cells and� t�ereby� 
reduces t�e iron absorption [��].
T�is is expected to affect t�e sensitivity of tumor 
cells to artemisinin and its derivatives. We observed 
t�at incubation of t�e �CF­� cells wit� different 
sensitivity to cytotoxic drugs wit� artemisinin expres­
sion of miR­���b� ­���a� and ­�4a c�anged �Fig­
ure�. In particular� t�e levels of miR­�4a and ­���a 
increased bot� in sensitive and resistant to Dox 
�CF­� cell lines. At t�e same time in all studied cells 
we observed increased levels of miR­���b. T�ese 
data suggest t�at t�e reduced sensitivity of �CF­�/
DDP to artemisinin is mediated not only by violations 
in regulating proteins levels. It can be caused by fea­
tures of epigenetic regulation of expression of proteins 
responsible for iron metabolism. T�ere are many 
reports of selective cytotoxicity of artemisinin and its 
derivatives on tumor cells of prostate� breast� larynx� 
blood and ot�er cancers. In addition� t�ere is t�e 
evidence t�at cell deat� occurs only by apoptosis be­
cause artemisinin does not induce necrosis. Necrotic 
cells release large amounts of cytokines after lysis� 
t�ereby inducing inflammation� w�ic� is one of t�e 
s�ortcomings of most anticancer drugs [��]. Selective 
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toxicity artemisinin on tumor cells and its low toxicity 
on normal breast cells were confirmed in experiments 
in vitro by Sing� et al. [��]. It is known t�at only one 
t�ird of circulating transferrin molecules are loaded 
wit� iron and oral iron salts significantly increase t�e 
concentration of iron ions in breast tumors. T�is is due 
to t�e fact t�at BC cells actively absorb iron from t�e 
blood. In in vivo experiments t�e possibility of increas­
ing t�e sensitivity of tumor cells to artemisinin by t�is 
way was demonstrated [��].
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Figure. Relative miR­�4a� ­���b� and ���a expression 
in �CF­� cells wit� different sensitivity to cytostatic drugs after 
artemisinin treatment compared to untreated control
Note: #coincides with Hargraves et al. results [19]; *р ≤ 0.05 compared with 
cell lines without artemisinin
Obtained data suggest artemisinin cytotoxic effect 
on BC cells and t�e ability of t�e drug to improve t�e 
sensitivity of tumor cells to anticancer drugs. In addi­
tion� t�e possibility of correction of t�erapeutic dose 
using a magnetic fluid t�at can be used to increase 
t�e sensitivity of transformed cells to t�e action of cy­
tostatics.
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